Dec 5
|
While Pfizer Faced A Setback, Altimmune, Roche And Mainz Biomed Advanced in The Battle Against Obesity And Colorectal Cancer
|
Dec 5
|
Roche (RHHBY) Breast Cancer Drug Meets Primary Goal in Phase III
|
Dec 5
|
The Fed Is Watching Jobs Data. Why It Should Be Listening to Spotify.
|
Dec 5
|
Genentech Announces Positive Phase III Results for Inavolisib Combination in People With Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer With a PIK3CA Mutation
|
Dec 5
|
Roche announces positive Phase III results for inavolisib combination in people with advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation
|
Dec 4
|
Roche Stock Rises On $3.1 Billion Deal For Obesity Drugmaker
|
Dec 4
|
Roche Buys Carmot Therapeutics to Compete in Booming Market for Weight-Loss Drugs
|
Dec 4
|
Roche (RHHBY) to Acquire Obesity Drug Maker Carmot for $2.7B
|
Dec 4
|
Roche: fat fighter drugs buy must precede trial wins
|
Dec 4
|
Roche Strikes $3.1 Billion Deal for Obesity Drugmaker. It’s Hoping to Compete with Eli Lilly, Novo Nordisk.
|
Dec 4
|
Roche bets on obesity market with Carmot deal
|
Dec 4
|
Roche to buy Carmot for up to $3.1bn as race for obesity drugs intensifies
|
Dec 4
|
Roche joins race for obesity drugs with $2.7 billion Carmot deal
|
Dec 4
|
Roche to Buy Carmot Therapeutics for Up to $3.1 Billion in Bet on Obesity Treatments
|
Dec 4
|
Roche to Buy Obesity Drug Maker Carmot for $3.1 Billion
|
Dec 4
|
Roche joins obesity drug chase with $2.7B deal for startup Carmot
|
Dec 4
|
UPDATE 4-Roche joins race for obesity drugs with $2.7 bln Carmot deal
|
Dec 4
|
Roche enters into a definitive merger agreement to acquire Carmot Therapeutics, including three clinical stage assets with best-in-class potential in obesity and diabetes
|
Nov 28
|
Roivant’s Matt Gline on raising capital and biotech’s outlook for 2024
|
Nov 27
|
Roche expands hepatitis diagnostics portfolio to help clinicians diagnose and monitor patients with acute or chronic hepatitis B infection
|